Why Nemaura, iBio And Cocrystal Are Moving Wednesday

Wednesday, 5 May 2021, 18:19:22
Nemaura Medical Inc. (NASDAQ: NMRD ), iBio, Inc. (NYSE: IBIO ) and Cocrystal Pharma, Inc. (NASDAQ: COCP ) are among the healthcare movers Wednesday. Nemaura Rallies On Receipt of Orders: Nemaura, a medtech company developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced the receipt of purchase orders for 5,000 sugarBEAT transmitters and 200,000 sugarBEAT sensors from its U.K. licensee DB Ethitronix. Nemaura expects an additional rolling monthly purchase order for the next 24 months of 15,000 transmitters and 2.1 million sensors, with an option to increase volumes based on customer response. sugarBEAT, a … Full story available on Benzinga.com
— Benzinga

Rookie Traders Get Crushed By Cocrystal Pharma Stock

Wednesday, 5 May 2021, 15:33:02
The trading in biotechnology company Cocrystal Pharma, Inc. (NASDAQ: COCP ) is a good example of how inexperienced traders can lose a lot of money. What Happened: Cocrystal closed Tuesday at $2.14, a gain of over 70%. At one point during the day, shares reached $3.46, which was about 270% higher than the previous close. This move was driven by news that the company was going to offer 26 million new shares … Full story available on Benzinga.com
— Benzinga

Cocrystal Pharma Shares Plunge On $40M Equity Raise At 28% Discount

Wednesday, 5 May 2021, 12:37:22
Cocrystal Pharma Inc (NASDAQ: COCP ) has entered into an underwriting agreement with H.C. Wainwright & Co LLC, under which the underwriter has agreed to purchase 26 million shares at $1.54 per share. The offer price is at a 28% … Full story available on Benzinga.com
— Benzinga

Why Cocrystal Pharma, Chemocentryx, Neuronetics And BioLineRx Are Moving Today

Tuesday, 4 May 2021, 19:45:43
Cocrystal Pharma, Inc. (NASDAQ: COCP ), ChemoCentryx, Inc. (NASDAQ: CCXI ), Neuronetics, Inc. (NASDAQ: STIM ) and BioLineRx Ltd. (NASDAQ: BLRX ) are among the biggest health care movers Tuesday. Cocrystal Shines On COVID-19 Pipeline: Cocrystal, a clinical-stage biotech engaged in the development of anti-viral therapeutics, announced Monday it is aggressively developing novel coronavirus protease inhibitors for COVID-19 prophylactic and therapeutic use. “These drug candidates bind to a highly conserved region of the active site of SARS-CoV-2 protease that is required for SARS-CoV-2 viral replication,” the company said. Due to their novel mechanism of action, these protease inhibitors are likely to be effective against new variants of SARS-CoV-2, it added. After a muted reaction on Monday, the stock has taken off Tuesday. Reacting … Full story available on Benzinga.com
— Benzinga

Cocrystal Doubles on Report of Progress on Covid Drugs – TheStreet

Tuesday, 4 May 2021, 19:05:46
Cocrystal Pharma shares doubled on Tuesday after it reported progress with its COVID-19 antiviral drug candidates.
— The Street